The chloramphenicol (Cm)-inducible emL4 gene of Tn1696 specifies nonenzymatic resistance to Cm and is regulated by attenuation. 
competes with the inhibitory action of the peptides, and erythromycin and the peptides footprint to overlapping sites at the peptidyl transferase center of23S rRNA. It is proposed that translatin of the cmLA and cat leaders transiently pauses upon synthesis ofthe inhibitor peptides. The predicted site ofpausing is identical to the leader site where long-term occupancy by a ribosome (ribosome slling) will activate downstream gene expression. We therefore propose the inducer, Cm, converts a peptide-paused ribosome to the stalled state. We discuss the idea that cooperativ between leader peptide and inducer is necessary for ribosome stalling and may link the activation of a specific drug-resistance gene with a particular antibiotic.
Translation attenuation regulates the antibiotic-inducible expression of several antibiotic-resistance genes (1) (2) (3) . In this form of gene control, the antibiotic to which a gene confers resistance is also the inducer of gene expression. Gene activation results when a ribosome becomes stalled at a unique site in the leader region of the regulated transcripts (2) . Stalling at this site alters the adjacent secondary structure, permitting translation of the downstream coding sequence (4) (5) (6) . The antibiotic inducers for attenuationregulated cat and erm genes, chloramphenicol (Cm) and erythromycin (Em), block translation at apparently random mRNA sites. Site specificity of ribosome stalling in the leaders is therefore not determined by the inducer but by the sequence of the leader (7) .
Studies by Gu et A ribosome occupying the induction site in the cat-86 leader has completed translation of the first five leader codons (9, 10) . It was therefore proposed that the leader pentapeptide cis inhibits PT, thereby pausing the translating ribosome at the induction site. This effect would increase the probability that Cm will encounter ribosomes in the leader that are poised for induction. Here we demonstrate that a truncated form of the leader peptide for a Cm-inducible gene that is unrelated to cat is also a highly effective in vitro inhibitor of PT (11) .
MATERIALS AND METHODS PT Assays. The fiagment reaction was used to measure PT activity (11) . Assays were performed on ice for 1 hr as described (8) ; replicates varied by <5%. Unless noted, Bacillus subtilis 50S ribosomes, 0.1-0.2 OD260 unit per reaction, were used as source ofPT. Ribosomes were isolated (12) from logarithmic phase cells of B. subtilis BR151 and Escherichia coli DH5aF' grown at 370C in penassay broth and Thermus aquaticus ATCC 25104 grown at 70"C in Castenholz medium as modified by Noller et al. (13) .
To quantitatively measure inhibition by a peptide, the peptide was preincubated with ribosomes for 10 min on ice as described (8) . The ribosome/peptide mixture (7 jld) was then added to a reaction cocktail to initiate the reaction. Concentrations of all reactants are reported on the basis of the 50-tA aqueous portion of the reaction cocktails (8 (15) (16) (17) (18) . cmlA expression depends on Cm-inducible attenuation regulation probably comparable to that controlling the expression of cat genes from Gram-positive bacteria (refs. 2, 19, 20; Fig. 1 ). Substituting the first seven, eight, or nine codons of the cmlA leader for the first five codons of the cat-86 leader demonstrated that only the first eight codons of the cmlA leader permitted Cm induction of the hybrid gene (E.J.R., unpublished data). This observation predicted that the cmlA 8-mer leader peptide, MSTSKNAD, would be inhibitory for PT (8) . We observed that the eight-residue leader peptide was an effective inhibitor of PT using 50S ribosomal subunits from either B. subtilis or E. coli (Fig. 2) . The reverse sequence of the 8-mer, DANKSTSM, was not Abbreviations: Cm, chloramphenicol; DMS, dimethyl sulfate; Em, erythromycin; PT, peptidyl transferase. *To whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" inhibitory nor were the 6, 7-, and 9-mer cmUA peptides (Fig.  2) Variations of the 8-mer and 5-mer peptides were tested at 250 A.M and 800 pM, respectively, using B. subtilis 50S ribosomes. The peptide SSTSKNAD was inhibitory for PT, although the concentration required for >95% inhibition was 4-fold higher than MSTSKNAD.
Notable differences between the 8-and 5-mer peptides were also observed. Converting the cmUA 8-mer to a 9-mer by the C-terminal addition of Lys abolished the inhibitory activity ( Fig. 2 and Table 1 ). Lys is the product of the ninth, and final, cmlA leader codon (Fig. 1) . This striking change in peptide activity brought about by adding a single residue could reflect the altered charge of the peptide, or its pattern of folding. This observation may be significant to the biology of the system, since it predicts that the version of the cmlA leader peptide released into the cytoplasm upon complete translation ofthe leader will not interfere with general protein synthesis. In contrast, addition to the C terminus ofthe cat-86 5-mer those amino acids specified by the last four codons of the leader, Lys, Ile, and two Ser residues, did not alter inhibition (Table 1) .
PT Extracted by Phenol from T. aquaticus Ribosomes Is Inhibited by the Peptides. The PT activity associated with the enriched rRNA that remains after phenol treatment of T. aquaticus ribosomes (13) was approximately as sensitive to peptide inhibition as intact 50S subunits of E. coli and B. subtilis ( Fig. 3 and compare with Fig. 2) . The reverse versions of the cat and cmIA peptides failed to inhibit the activity. The deproteinization method used leaves up to eight ribosomal proteins associated with the 23S rRNA (22) . It therefore remains possible that the inhibitor peptides act, in part, on ribosomal protein. Intact T. aquaticus 50S subunits were less sensitive to peptide inhibition than the deproteinized 23S rRNA (Fig. 3) . It is possible that in these ribosomes the target for peptide inhibition is masked by proteins that can be removed by phenol.
Effects of Em and Cm on Peptide Inhibition. Due to its sites of interaction with the 50S subunit, Em is a competitor of Cm (23) . We observed that addition of Em to ribosomes prior to peptide or simultaneously with the peptide partially reversed peptide inhibition of PT (Fig. 4) ; competition was most effective when the antibiotic was added prior to peptide. Streptomycin did not interfere with the activity of the inhibitor peptides (Fig. 4) and this antibiotic does not compete with Cm.
PT inhibition by Cm follows two slopes (Fig. 2) . At concentrations above 150 ,uM inhibition becomes asymptotic. Ribosomes preincubated with saturating levels of Cm were exposed to increasing concentrations of 8-mer peptide. The resulting inhibition of PT was quantitatively comparable to peptide inhibition ofribosomes not preexposed to Cm (Fig.  4) . These data suggest additive inhibition of PT by the cmUA 8- (14) .
Exposure of ribosomes to Em diminishes DMS methylation of nt 2058 and 2059 in 23S rRNA (ref. 24; see Fig. 5 ) as evidenced by a reduction in reverse transcriptase drop-offs at the two preceding nucleotides, 2059 and 2060. This was confirmed for B. subtilis ribosomes (Fig. 6 Upper, compare "No inhibitor" and "Em" lanes). Exposure of ribosomes to the inhibitor peptides diminished the methylation of these same nucleotides since reverse transcriptase drop-offs at 2059 and 2060 became reduced, but not to the extent seen with Em (Fig. 6 Upper, "8-mer" lane; Fig. 6 Lower, "5-mer" lane). A footprint unique to the peptides was observed at the adjacent nt 2060, which became sensitive to DMS methylation as a consequence of prior exposure to the peptides and is disclosed by termination of reverse transcriptase at the preceding nucleotide, 2061 (Fig. 6 Upper, "8-mer"; Fig. 6 Lower, "5-mer"). Two other sites ofpeptide-enhanced methylation, at nt 2071 and 2077, can be seen in Fig. 6 Drug-peptide combinations were added to ribosomes simultaneously (Em+8-mer) for a 10-min preincubation or drug was added to ribosomes 5 min prior to peptide and the combination was incubated for an additional 10 min prior to assay (Em'+8-mer). Cm. In terms of PT activity, the 100lo value for the Cm-treated ribosomes is 48% of the PT activity of ribosomes not exposed to Cm.
with ribosomes prior to DMS treatment ( Fig. 6 ; "Rev 8-mer," "8-mer Pro," "8-mer Gly," "Rev 5-mer"). DISCUSSION Selection of a ribosome stall site through the inhibitory activity of a nascent leader peptide is novel among genes regulated by attenuation (29) . Variations of this concept have been suggested as the basis for two other examples of translational regulation (30, 31) . Peptides exit the ribosome from a site associated with the PT center (32) , predicting that any regulation due to a nascent peptide will probably be focused on the 50S subunit. Our observations adequately explain a form of ribosome pausing that occurs in bacteria. It remains to be determined if our conclusions can account for examples of translational pausing, or stalling, that occur in eukaryotes (33, 34) .
In systems that are known to be regulated by translation attenuation, a correlation generally exists between the nature 
PT center in 23S rRNA. Sites to which Em and the peptides footprint are indicated. Nucleotides were numbered in accordance with E. coli 23S rRNA (24) . The annealing site for the primer used to initiate reverse transcriptase is shown. (8) . These peptides were tested at 500 ,tLM. The 23S rRNA in B. subtilis differs slightly in size from E. coli 23S rRNA (25) . The numbering of nucleotides used here corresponds to the E. coli system. leader peptide binding to a ribosome exposes a novel Cm target, which allows the antibiotic to irreversibly damage the ribosome.
The induction of ermC by Em also depends on the sequence of the leader peptide (36) . We therefore suggest that selection of the ribosome pause site in translation attenuation regulation is likely to be one biological function of the leader peptides.
